ESPR Esperion Therapeutics Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on December 9, 2022, the Compensation Committee of Esperion’s Board of Directors granted 2 new employees 5,600 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.

The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient’s vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion’s 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant.

Esperion Therapeutics

Esperion works hard to make our medicines easy to get, easy to take and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate, and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. Esperion is the leader in the development of convenient oral, once-daily non-statin LDL-cholesterol lowering drugs for patients with high levels of bad cholesterol. For more information, please visit and follow us on Twitter at .

Contact:

Corporate Communications



EN
13/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Esperion Therapeutics Inc.

 PRESS RELEASE

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conf...

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference ANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion Therapeuti...

 PRESS RELEASE

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of ...

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026 –  Analysis Demonstrated 22% Reduced Risk of Ischemic Stroke for Patients Taking Bempedoic Acid Compared to Placebo – – Analysis of CLEAR Outcomes Reports Bempedoic Acid Reduced MACE in High-Risk Patients with Autoimmune or Inflammatory Diseases (AIID) Similarly to Those Without AIID – ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of two post-hoc analyses fro...

 PRESS RELEASE

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Tria...

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management ANN ARBOR, Mich., March 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that two abstracts have been accepted for presentation in moderated poster sessions at the upcoming American College of Cardiology’s 2026 Annual Scientific Session (ACC.26) taking place March 28-30, 2026 in New Orl...

 PRESS RELEASE

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in...

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia – Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia – – Bempedoic Acid Receives Equal Positioning with PCSK9 mAb and Ezetimibe After Statins for High-Risk Primary Prevention and Clinical ASCVD Not at Very High-Risk Patients – – Guideline Recognition of Early Combination Lipid-Lowering Therapy and Reintrod...

 PRESS RELEASE

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results a...

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch